Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00454571
Recruitment Status : Completed
First Posted : March 30, 2007
Results First Posted : February 10, 2016
Last Update Posted : February 10, 2016
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This randomized phase II trial is studying how well pazopanib hydrochloride works after leuprolide or goserelin in treating patients with relapsed prostate cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate or goserelin acetate, may lessen the amount of androgens made by the body. Giving pazopanib after leuprolide or goserelin may be an effective treatment for prostate cancer

Condition or disease Intervention/treatment Phase
Recurrent Prostate Cancer Drug: pazopanib hydrochloride Drug: leuprolide acetate Drug: goserelin acetate Phase 2

Detailed Description:


I. Determine if pazopanib hydrochloride is able to increase time to progression, as measured by prostate-specific antigen (PSA), after 6 months of limited gonadotropin-releasing hormone (GnRH) agonist therapy comprising leuprolide acetate or goserelin in patients with androgen-sensitive relapsed stage D0 prostate cancer.


I. Determine the adverse events in patients treated with this regimen. II. To monitor for changes in testosterone in relationship to pazopanib therapy versus observation.


Patients receive androgen blockade comprising GnRH agonist therapy (e.g., leuprolide acetate or goserelin acetate) for 6 months. Patients who develop metastases or have PSA progression while on GnRH agonist therapy are removed from the study and placed on total androgen blockade. The remaining patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo observation.

After completion of study treatment, patients are followed up periodically for up to 12 months.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Study Start Date : June 2006
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Arm Intervention/treatment
Experimental: Pazopanib
Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: pazopanib hydrochloride
Given PO
Other Names:
  • GW786034B
  • Votrient
Drug: leuprolide acetate
Other Names:
  • Enantone
  • LEUP
  • Lupron
  • Lupron Depot
Drug: goserelin acetate
Other Names:
  • ICI-118630
  • ZDX
  • Zoladex
Active Comparator: Observation
Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
Drug: leuprolide acetate
Other Names:
  • Enantone
  • LEUP
  • Lupron
  • Lupron Depot
Drug: goserelin acetate
Other Names:
  • ICI-118630
  • ZDX
  • Zoladex

Primary Outcome Measures :
  1. Median Time to PSA Progression [ Time Frame: Baseline, every 4 weeks during treatment, and up to 12 months after completion of study treatment ]
    The median time to disease progression for the therapy and observation groups will be estimated using the Kaplan-Meier estimate and compared using the log-rank test.

Secondary Outcome Measures :
  1. Median PSA Progression-free Survival [ Time Frame: Time from randomization to PSA progression or death from any cause ]
    Kaplan-Meier estimates for PSA progression-free survival will be computed for the pazopanib and active surveillance groups and compared using the log rank test. The outcome measure is median PSA progression-free survival time.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed prostate cancer

    • Stage D0
  • Must have undergone some definitive local therapy for prostate cancer
  • Must be free of macrometastatic disease, as evidenced by computed tomography (CT) scan and bone scan, if serum PSA ≥ 10 ng/mL prior to GnRH agonist therapy
  • Progressive disease meeting the following criteria: NOTE: Patients who have undergone a prostatectomy and have two detectable, rising serum PSA levels are eligible

    • Two consecutive rises in PSA above nadir recorded after definite local therapy
    • Serum PSA concentrations must have absolute value of > 0.5 ng/mL (separated by ≥ 2 weeks) prior to beginning GnRH agonist therapy
  • PSA < 0.5 ng/mL
  • Testosterone < 30 ng/mL
  • No measurable disease
  • No brain metastases requiring steroid or anticonvulsant therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60- 100%
  • Prothrombin time (PT)/international normalization ratio (INR)/partial thromboplastin time (PTT) ≤ 1.2 times upper limit of normal (ULN)
  • Bilirubin normal
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN
  • Creatinine ≤ 1.5 times ULN OR creatinine clearance > 50 mL/min
  • Proteinuria ≤ 1+ on 2 consecutive dipsticks > 1 week apart
  • Urine protein: creatinine ratio < 1 OR urine protein < 1.0 g/24 hours
  • Fertile patients must use effective double-barrier contraception during study therapy OR completely abstain from sexual intercourse 14 days prior to, during, and for ≥ 21 days after completion of study therapy
  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or to other agents used in the study
  • No concurrent uncontrolled illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Psychiatric illness or social situations that would preclude compliance with study requirements
  • No human immunodeficiency virus (HIV) positivity
  • No condition that impairs the ability to swallow and retain pazopanib hydrochloride tablets, including any of the following:

    • Gastrointestinal tract disease resulting in an inability to take oral medication
    • Requirement for intravenous (IV) alimentation
    • Prior surgical procedures affecting absorption
    • Active peptic ulcer disease
  • No other conditions, including any of the following:

    • Serious or nonhealing wound, ulcer, or bone fracture
    • Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
    • Cerebrovascular accident within the past 6 months
    • Myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the past 6 months
    • Venous thrombosis within the past 12 weeks
    • New York Heart Association (NYHA) class III or IV heart failure

      • History of currently treated asymptomatic NYHA class II heart failure allowed
  • Systolic blood pressure (BP) ≤ 140 mm Hg and diastolic BP ≤ 90 mm Hg

    • Prior initiation or adjustment of BP medication allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg
  • More than 3 months since prior antiandrogen
  • More than 4 months since prior orchiectomy or implantable luteinizing LHRH agonist
  • No prior GnRH agonists except for neoadjuvant or adjuvant therapy associated with local therapy

    • Patients who have started a GnRH agonist for micrometastatic disease after local therapy allowed provided the following criteria are met:

      • Progressive disease
      • Willing to discontinue therapy before 6 months have elapsed
      • Have signed consent prior to completing 6 months of the initial hormone therapy
      • Are within 4 months of initiating GnRH agonist therapy
  • No prior or concurrent GnRH antagonist therapy
  • No concurrent ketoconazole
  • No concurrent cytochrome P450 2C9 (CYP2C9) substrates, including any of the following:

    • Anticoagulants (e.g., warfarin [therapeutic doses only])

      • Low molecular weight heparin or prophylactic low-dose warfarin allowed
    • Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)
    • Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
    • Neuroleptics (e.g., pimozide)
    • Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)
    • Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexiletin, amiodarone, quinidine, or propafenone)
    • Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)
    • Miscellaneous medications (e.g., theophylline, quetiapine, risperidone, tacrine, clozapine, or atomoxetine)
  • No concurrent medications associated with the risk of QTc prolongation and/or Torsades de Pointes

    • Replacement of drugs that do not carry these risks allowed
  • No other concurrent non-Food and Drug Administration (FDA)-approved agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00454571

United States, Illinois
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States, 60637-1470
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Edwin Posadas University of Chicago Comprehensive Cancer Center

Publications of Results:
Responsible Party: National Cancer Institute (NCI) Identifier: NCT00454571     History of Changes
Other Study ID Numbers: NCI-2009-00202
N01CM62201 ( U.S. NIH Grant/Contract )
CDR0000538086 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: March 30, 2007    Key Record Dates
Results First Posted: February 10, 2016
Last Update Posted: February 10, 2016
Last Verified: September 2012

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents